News & Updates
Showing Endocrinology articles
Showing
Show Multimedia Only

Romosozumab improves bone health in osteoporotic women with diabetes
27 Sep 2025
byStephen Padilla
Treatment with romosozumab for 12 months, followed by 24 months of alendronate, results in significant improvements in lumbar spine areal bone mineral density (BMD) and tissue thickness-adjusted trabecular bone score (TBS) algorithm (TBSTT) compared with alendronate alone among postmenopausal women with osteoporosis and type 2 diabetes (T2D), reports a study.








